title: Candidate cancer-targeting agents identified by expression-profiling arrays.
abstract: BACKGROUND
  One particularly promising component of personalized medicine in cancer treatment is targeted therapy, which aims to maximize therapeutic efficacy while minimizing toxicity. However, the number of approved targeted agents remains limited. Expression microarray data for different types of cancer are resources to identify genes that were upregulated. The genes are candidate targets for cancer-targeting agents for future anticancer research and targeted treatments.
  
  
  RESULTS
  The gene expression profiles of 48 types of cancer from 2,141 microarrays reported in the Gene Expression Omnibus were analyzed. These data were organized into 78 experimental groups, on which we performed comprehensive analyses using two-tailed Student's t-tests with significance set at P < 0.01 to identify genes that were upregulated compared with normal cells in each cancer type. The resulting list of significantly upregulated genes was cross-referenced with three categories of protein inhibitor targets, categorized by inhibitor type ('Targets of US Food and Drug Administration (FDA)-approved anticancer drugs', 'Targets of FDA-approved nonantineoplastic drugs', or 'Targets of non-FDA-approved chemical agents'). Of the 78 experimental groups studied, 57 (73%) represent cancers that are currently treated with FDA-approved targeted treatment agents. However, the target genes for the indicated therapies are upregulated in only 33 of these groups (57%). Nevertheless, the mRNA expression of the genes targeted by FDA-approved treatment agents is increased in every experimental group, including all of the cancers without FDA-approved targeted treatments. Moreover, many targets of protein inhibitors that have been approved by the FDA as therapies for nonneoplastic diseases, such as 3-hydroxy-3-methylglutaryl-CoA reductase and cyclooxygenase-2 and the targets of many non-FDA-approved chemical agents, such as cyclin-dependent kinase 1 and DNA-dependent protein kinase, are also overexpressed in many types of cancer.
  
  
  CONCLUSIONS
  This research demonstrates a clinical correlation between bioinformatics data and currently approved treatments and suggests novel uses for known protein inhibitors in future antineoplastic research and targeted therapies.
authors: Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors: Vittavat
authors: V
authors: Termglinchan
authors: Wachiraporn
authors: W
authors: Wanichnopparat
authors: Kulachanya
authors: K
authors: Suwanwongse
authors: Chunhakarn
authors: C
authors: Teeyapant
authors: Kanticha
authors: K
authors: Chatpermporn
authors: Kanchana
authors: K
authors: Leerunyakul
authors: Khwanruthai
authors: K
authors: Chuadpia
authors: Onpailin
authors: O
authors: Sirimaneethum
authors: Parinya
authors: P
authors: Wijitworawong
authors: Wattanakitch
authors: W
authors: Mutirangura
authors: Chatchawit
authors: C
authors: Aporntewan
authors: Chanida
authors: C
authors: Vinayanuwattikun
authors: Apiwat
authors: A
authors: Mutirangura
keywords: cancer treatment; personalized medicine; protein inhibitor; targeted therapy; upregulated gene expression
references: Cancer Chemother Pharmacol. 2012 Jun;69(6):1657-67
references: 22349810
references: Am J Clin Oncol. 1998 Dec;21(6):579-83
references: 9856659
references: Nucleic Acids Res. 2002 Jan 1;30(1):207-10
references: 11752295
references: Ann Intern Med. 2007 Mar 6;146(5):376-89
references: 17339623
references: Br J Cancer. 2007 Jan 15;96(1):29-37
references: 17179992
references: Cancer Lett. 2011 Oct 1;309(1):19-26
references: 21652147
references: Nat Rev Drug Discov. 2012 Apr 30;11(5):339-40
references: 22543457
references: Anticancer Res. 1996 Mar-Apr;16(2):1027-32
references: 8687094
references: Cancer Cell. 2008 Jun;13(6):472-82
references: 18538731
references: Eur J Cancer. 2010 Dec;46(18):3243-50
references: 20822897
references: N Engl J Med. 2002 Aug 15;347(7):472-80
references: 12181401
references: Eur J Haematol. 2007 Sep;79(3):240-3
references: 17655704
references: Br J Cancer. 2001 Apr 6;84(7):886-91
references: 11286466
references: Med Res Rev. 2010 Jan;30(1):102-35
references: 19526461
references: Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15051-6
references: 20696928
references: Nature. 2007 Aug 9;448(7154):645-6
references: 17687303
references: Clin Cancer Res. 2012 Feb 15;18(4):1129-37
references: 22228638
references: Oncogene. 2012 Nov 29;31(48):4967-78
references: 22310279
references: Expert Opin Investig Drugs. 2006 Nov;15(11):1295-8
references: 17040191
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Eur J Neurol. 2004 Feb;11(2):141
references: 14748776
references: Cancer. 2012 Dec 15;118(24):6055-62
references: 22674198
references: Cell. 2009 Mar 6;136(5):823-37
references: 19269363
references: Leukemia. 2002 Apr;16(4):508-19
references: 11960327
references: Cancer Chemother Pharmacol. 2012 Nov;70(5):707-16
references: 22941374
references: Gynecol Oncol. 2012 Oct;127(1):55-62
references: 22664059
references: N Engl J Med. 2006 Aug 31;355(9):873-84
references: 16943400
references: Gastroenterology. 2006 Dec;131(6):1674-82
references: 17087947
references: Br J Cancer. 2010 Aug 24;103(5):622-8
references: 20683448
references: Br J Clin Pharmacol. 2007 Nov;64(5):563-5
references: 17935601
references: Lancet Oncol. 2010 Jul;11(7):685-93
references: 20362508
references: N Engl J Med. 2012 Nov 8;367(19):1792-802
references: 23134381
references: Int J Biol Sci. 2007 Jun 13;3(5):328-34
references: 17589567
references: Transplantation. 2005 Oct 15;80(2 Suppl):S254-64
references: 16251858
references: Oral Oncol. 2010 Dec;46(12):880-7
references: 20951077
references: BMC Cancer. 2010 Jul 19;10:376
references: 20637128
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D1005-10
references: 21097893
references: BMC Cancer. 2006 Jan 30;6:27
references: 16445867
references: N Engl J Med. 2005 Jul 14;353(2):172-87
references: 16014887
references: BMC Cancer. 2008 Aug 14;8:237
references: 18702823
references: J Health Econ. 1991 Jul;10(2):107-42
references: 10113009
references: Curr Cancer Drug Targets. 2009 Aug;9(5):626-38
references: 19508172
references: Blood. 2007 Apr 1;109(7):2999-3006
references: 17158228
references: Clin Cancer Res. 2004 Oct 1;10(19):6703-9
references: 15475461
references: N Engl J Med. 2007 Jul 5;357(1):39-51
references: 17611206
references: BMC Genomics. 2009 Aug 07;10:365
references: 19660143
references: Clin Cancer Res. 2005 Mar 1;11(5):2089-96
references: 15756036
references: N Engl J Med. 2002 Feb 28;346(9):683-93
references: 11870247
references: Cancer Lett. 2008 Feb 18;260(1-2):11-9
references: 18180097
references: Mol Cancer Res. 2006 Feb;4(2):79-92
references: 16513839
references: N Engl J Med. 2011 Mar 24;364(12):1087-9
references: 21428763
references: N Engl J Med. 2006 Aug 31;355(9):885-95
references: 16943401
references: N Engl J Med. 2011 Oct 6;365(14):1273-83
references: 21991949
references: Mol Syst Biol. 2007;3:124
references: 17625512
references: Neuro Oncol. 2009 Oct;11(5):477-87
references: 19139420